European Commission Approval for YESAFILI®, Biosimilar Aflibercept #education #clinicalstudy

Source Link: www.biocon.com/biocon-biologics-receives-european-…

Biocon Ltd., has received marketing authorization from the European Commission (EC) for YESAFILI®, a biosimilar of Aflibercept. This approval allows YESAFILI® to be used in the European Union (EU) for the treatment of various eye conditions, including age-related macular degeneration and diabetic macular edema. The decision follows a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). YESAFILI® is similar in quality, safety, and efficacy to the reference product Eylea®, and this authorization is valid in all EU Member States and European Economic Area (EEA) countries. Aflibercept had significant sales in the EU, making this approval a significant development for Biocon Biologics in expanding its biosimilar portfolio for patients in need of these treatments.